Study guide
10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
Key Takeaways Explain This Topic AI
First-line treatment of anaphylaxis is intramuscular adrenaline 0.01 mg/kg (maximum 0.5 mg in adults) into the anterolateral thigh, repeated after 5 minutes if needed.
Serum tryptase is best taken about 1 to 2 hours after the onset of anaphylaxis and compared with a baseline sample taken at least 24 hours after the reaction.
In peanut allergy, sensitisation to the storage protein Ara h 2 predicts systemic reactions, whereas Ara h 8, a Bet v 1 homologue, is linked to mild oral allergy syndrome.
Venom immunotherapy is usually given for 3 to 5 years, and lifelong treatment is considered in patients with mastocytosis or a raised baseline tryptase after a severe sting reaction.
Alpha-gal syndrome, triggered by tick bites, causes delayed urticaria or anaphylaxis about 3 to 6 hours after eating red meat.
Last updated: September 2026
10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
Allergology is part of Session 2 of the official timetable. Dermatologists in many European countries carry out allergy testing themselves, so questions test both the tests and emergency care.
Mechanism
In type I hypersensitivity , a first exposure produces allergen-specific IgE , which binds the high-affinity receptor FcεRI on mast cells and basophils ( sensitisation ). On re-exposure, the allergen cross-links IgE, and the cells release histamine, tryptase, leukotrienes, and prostaglandins within minutes. Symptoms include urticaria, angioedema, rhinoconjunctivitis, asthma, gut symptoms, and anaphylaxis. A late-phase reaction can follow after 4–8 hours.
Non-IgE mast cell activation (formerly "pseudoallergy") can mimic allergy. Examples are the MRGPRX2 receptor (fluoroquinolones, neuromuscular blocking agents, icatibant), NSAID cross-intolerance through COX-1 inhibition, radiocontrast media, and opioids.
Diagnostic Tests
Test Use and Key Points
Skin prick test (SPT) Standardised extracts pricked into the forearm, read at 15–20 minutes; positive control histamine and negative control saline; a wheal ≥ 3 mm greater than the negative control is positive. Stop oral antihistamines several days before. Positive tests show sensitisation, which is significant only with a matching history
Intradermal test More sensitive; used for drugs and venoms ; higher risk of systemic reactions
Specific IgE Serum test (for example ImmunoCAP); useful with extensive eczema, dermographism, or if antihistamines cannot be stopped
Component-resolved diagnostics Tests IgE to individual molecules to estimate risk (see table below)
Basophil activation test Flow cytometry of CD63 or CD203c after allergen exposure; helpful for drugs, venoms, and foods in specialist centres
Oral food or drug provocation test The gold standard; done under supervision with resuscitation available; contraindicated after SJS/TEN or DRESS
Serum tryptase Taken about 1–2 hours after the start of a reaction and compared with a baseline taken at least 24 hours later . A peak above (1.2 × baseline) + 2 ng/mL supports mast cell activation. A raised baseline suggests mastocytosis or hereditary alpha-tryptasaemia
Important Allergen Components
- Component Source Meaning
- Ara h 2 (2S albumin) Peanut High risk of systemic reactions
- Ara h 8 Peanut (Bet v 1 homologue) Cross-reactivity with birch pollen; usually mild oral allergy syndrome
- Bet v 1 Birch pollen Pollen-food syndrome with apple, hazelnut, carrot, stone fruits
Lipid transfer proteins (for example Pru p 3, peach) Plant foods Stable proteins; severe reactions, common in Southern Europe
- Tri a 19 (omega-5 gliadin) Wheat Food-dependent exercise-induced anaphylaxis
- Tropomyosin Shellfish, mites Cross-reactivity between crustaceans and house dust mites
Galactose-alpha-1,3-galactose (alpha-gal) Red meat, cetuximab Delayed anaphylaxis 3–6 hours after red meat, after tick bites
Api m 1 ; Ves v 1, Ves v 5 Honeybee; wasp (yellow jacket) Separate true double sensitisation from cross-reactivity when choosing venom immunotherapy
Anaphylaxis
Anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction. It is likely when skin or mucosal symptoms appear suddenly with airway, breathing, or circulation problems , or when two or more organ systems are involved after likely allergen exposure. Skin signs are absent in a minority of cases.
Emergency Treatment
Call for help, and remove the trigger if possible.
Intramuscular adrenaline (epinephrine) 1 mg/mL into the anterolateral thigh: 0.01 mg/kg, maximum 0.5 mg in adults . Repeat after 5 minutes if there is no improvement.
Lie the patient flat with legs raised (or sitting if breathless; left side if pregnant). Do not stand them up suddenly.
High-flow oxygen, IV fluids for hypotension, and inhaled bronchodilators for wheeze.
Antihistamines and corticosteroids are second-line . They do not treat airway obstruction or shock.
Observe for a possible biphasic reaction , take tryptase samples, and refer to an allergist.
Prescribe two adrenaline auto-injectors with training and a written action plan. Adult devices usually contain 0.3 mg or more; 0.15 mg devices are for small children.
Risk factors for severe reactions: uncontrolled asthma, older age, cardiovascular disease, mastocytosis, beta-blocker or ACE inhibitor use, and cofactors such as exercise, alcohol, NSAIDs, and infection.
Food Allergy
IgE-mediated: milk, egg, peanut, tree nuts, sesame, fish, and shellfish. Symptoms begin within minutes to 2 hours.
Pollen-food syndrome: itching of the mouth and throat from raw fruit and vegetables in pollen-allergic patients (for example birch and apple). Cooking usually destroys these labile proteins.
Management: avoidance, clear labelling advice, an emergency plan, and adrenaline for those at risk. Oral immunotherapy for peanut is available for children in the EU under specialist supervision.
Early introduction of peanut and egg in infancy reduces the risk of developing allergy in high-risk infants.
Hymenoptera Venom Allergy
Large local reaction: swelling over 10 cm lasting more than 24 hours, next to the sting. The risk of a later systemic reaction is low.
Systemic reaction: from generalised urticaria to anaphylaxis.
Diagnosis: skin tests (prick and intradermal), specific IgE and components, and baseline tryptase . A raised baseline tryptase or mastocytosis predicts severe reactions.
Venom immunotherapy (VIT): indicated after systemic reactions beyond the skin, and in adults with generalised skin reactions when risk factors are present. It is highly effective (wasp VIT more than honeybee VIT). It is usually given for 3–5 years , and lifelong VIT is considered in mastocytosis , very severe reactions, or ongoing high exposure (beekeepers).
Immediate Drug Allergy
Beta-lactams: most patients labelled "penicillin allergic" can tolerate penicillin after assessment. Delabelling by skin testing and drug provocation reduces the use of broad-spectrum alternatives. Cross-reactivity with cephalosporins depends mainly on similar R1 side chains (for example amoxicillin with cefadroxil). Cross-reactivity with carbapenems is about 1%.
NSAIDs: most reactions are cross-intolerance from COX-1 inhibition (NSAID-exacerbated respiratory disease, cutaneous disease, or NSAID-induced urticaria and angioedema). Selective COX-2 inhibitors are usually tolerated. A smaller group react to a single NSAID through an allergic mechanism.
Perioperative anaphylaxis: neuromuscular blocking agents, antibiotics, chlorhexidine , patent blue dye, and latex.
Latex Allergy
Immediate IgE allergy to natural rubber latex proteins (Hev b allergens) mainly affected healthcare workers and children with spina bifida. It is linked to the latex-fruit syndrome (banana, avocado, kiwi, chestnut). Delayed contact allergy to rubber accelerators (thiurams, carbamates) is a different, type IV problem.
Allergen Immunotherapy (AIT)
AIT gives increasing doses of the allergen subcutaneously (SCIT) or sublingually (SLIT) for about 3 years . It induces allergen-specific IgG4 blocking antibodies , regulatory T cells, and IL-10, producing long-lasting tolerance. Indications include allergic rhinitis with or without asthma (grass, birch, house dust mite) and venom allergy. Uncontrolled asthma is a contraindication, and SCIT injections need about 30 minutes of observation afterwards.